H.C. Wainwright maintained a Buy rating with a $90 price target, emphasizing the potential of brensocatib for treating bronchiectasis in patients with Alpha-1 antitrypsin deficiency. Cantor Fitzgerald reiterated an Overweight rating, expressing optimism about Insmed's Treprostinil Palmitil Inhalation Powder (TPIP) for pulmonary arterial hypertension. RBC Capital Markets reaffirmed their Outperform rating with a $100 price target, highlighting the anticipated data for TPIP and its market potential. These developments reflect a growing interest in Insmed's innovative treatments and their potential impact on serious diseases.